Data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies, that selectively kills cancer cells and is thousands-fold better tolerated by healthy cells than previous NAMPT inhibitors. First presentation showcasing Remedy Plan’s unique,…